Clinical trial · no report yet · Phase 1
RACIN
RACIN in Patients With Advanced TIL-negative Solid Tumors
- NCT03728179 ↗
- Completed
- Centre Hospitalier Universitaire Vaudois
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- RACIN, A Phase I Study of the Combination of Nivolumab Associated With Low-dose Radiation, Aspirin/ Celecoxib, and Either Ipilimumab or Low-dose Cyclophosphamide, Followed by Nivolumab Maintenance, in Patients With Advanced, TIL-negative Solid Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Solid Tumor, Adult
- Interventions
- Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort 3a · Experimental
- Cohort 4a · Experimental
- Phase I b · Experimental
- Cohort 3b · Experimental
- Cohort 4b · Experimental
- Enrollment
- 40
- Primary outcomes
- Phases Ia and Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Maximum Tolerated dose (MTD) or recommended phase Ib dose of low-dose irradiation for radio-immunotherapy combination (RP1bD).
- Sponsor
- Centre Hospitalier Universitaire Vaudois
- Start
- Jan 16, 2019
- Primary completion
- Oct 27, 2023
- Results posted
- No
- Registry record
- NCT03728179 · updated Feb 20, 2024